Current Heart Failure Reports最新文献_第10页

Role of the Renal Lymphatic System in Heart Failure. 肾淋巴系统在心力衰竭中的作用。

Current Heart Failure Reports Pub Date : 2023-04-01 DOI: 10.1007/s11897-023-00595-0

Husam M Salah, Jan Biegus, Marat Fudim

{"title":"Role of the Renal Lymphatic System in Heart Failure.","authors":"Husam M Salah, Jan Biegus, Marat Fudim","doi":"10.1007/s11897-023-00595-0","DOIUrl":"https://doi.org/10.1007/s11897-023-00595-0","url":null,"abstract":"Purpose of review: The lymphatic system plays a major but overlooked role in maintaining fluid homeostasis. Given the unique fluid homeostasis functions of the kidneys, dysregulation of the renal lymphatic system underlies the development of self-propagating congestive pathomechanisms. In this review, we outline the roles of the renal lymphatic system in heart failure (HF).Recent findings: Studies have uncovered several pathomechanisms involving the renal lymphatic system in congestive states, such as impaired interstitial draining by the renal lymphatic system, impaired structure and valves of renal lymphatics, lymphatic-induced increase in renal reabsorption of water and sodium, and development of albuminuria with proteinuria-induced renal lymphangiogenesis. These self-propagating mechanisms result in \"renal tamponade\" with manifestations of cardiorenal syndrome and inappropriate renal response to diuretics. Dysregulation of the renal lymphatic system is integral to the development and progression of congestion in HF. Targeting renal lymphatics may provide a novel pathway to treat intractable congestion.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 2","pages":"113-120"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9427187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Sex Differences in Acute Heart Failure Management: Is There a Gap in Treatment Quality? 急性心力衰竭治疗的性别差异:治疗质量是否存在差距?

Current Heart Failure Reports Pub Date : 2023-04-01 DOI: 10.1007/s11897-023-00593-2

Elena Collado-Lledó, Francisco de la Cuerda, Albert Ariza-Solé

{"title":"Sex Differences in Acute Heart Failure Management: Is There a Gap in Treatment Quality?","authors":"Elena Collado-Lledó, Francisco de la Cuerda, Albert Ariza-Solé","doi":"10.1007/s11897-023-00593-2","DOIUrl":"https://doi.org/10.1007/s11897-023-00593-2","url":null,"abstract":"Purpose of review: Differences between men and women in demographics and clinical phenotype of heart failure have previously been described, as well as disparities in management and outcomes. This review summarizes the latest evidence concerning sex-related differences in acute heart failure and its most severe form, cardiogenic shock.Recent findings: Data from the last 5 years reaffirm the previous observations, with women with acute heart failure being older, more often having preserved ejection fraction and less frequently having an ischemic cause of the acute decompensation. Despite women still receive less invasive procedures and a less optimized medical treatment, the most recent studies find similar outcomes regardless of sex. These disparities persist in the context of cardiogenic shock, where women receive less mechanical circulatory support devices even if they present with more severe forms. This review reveals a different clinical picture of women with acute heart failure and cardiogenic shock compared to men, which translates into disparities in management. More female representation in studies would be needed in order to better understand the physiopathological basis of these differences and minimize inequalities in treatment and outcomes.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 2","pages":"121-128"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9428857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Sudden Death in Men Versus Women with Heart Failure. 男性与女性心力衰竭患者的猝死

Current Heart Failure Reports Pub Date : 2023-04-01 DOI: 10.1007/s11897-023-00596-z

Jorge Martínez-Solano, Manuel Martínez-Sellés

{"title":"Sudden Death in Men Versus Women with Heart Failure.","authors":"Jorge Martínez-Solano, Manuel Martínez-Sellés","doi":"10.1007/s11897-023-00596-z","DOIUrl":"https://doi.org/10.1007/s11897-023-00596-z","url":null,"abstract":"Purpose of review: Sudden cardiac death (SCD) represents the most feared complication of heart failure (HF). This review intends to provide insight on our current knowledge of sex differences in SCD mechanisms, prevention, and management in HF patients.Recent findings: Women with HF present a better prognosis than men and have a lower incidence of SCD, irrespective of the presence of ischemic heart disease and age. The influence of sex hormones, sex differences in intracellular calcium handling, and a differential myocardial remodeling may explain such a gap between men and women. Both HF drugs and ventricular arrhythmias ablation seems also useful for the management of women at risk of SCD, but special care must be taken with the use of antiarrhythmic QT-prolonging drugs. However, implantable cardioverter defibrillator (ICD) use has not been shown to be equally effective in women than men. Sex-specific recommendations regarding SCD in HF are still lacking due to the scarcity of information and the under-representation of women in clinical trials. Further investigation is required to provide specific risk stratification models in women. Cardiac magnetic resonance imaging, genetics development, and personalized medicine will probably play an increasing role in this evaluation.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 2","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9482566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. 心力衰竭伴射血分数降低和慢性肾脏疾病的疾病修饰疗法滴定的挑战和机遇。

Current Heart Failure Reports Pub Date : 2023-04-01 DOI: 10.1007/s11897-023-00594-1

Stefana Enachi, Maxime Schleef, Chahr-Eddine Hadjseyd, Simon Leboube, Charles Fauvel, Lucie Daniel, Antoine Jobbe-Duval, Laurent Sebbag, Sandrine Lemoine, Nathan Mewton

{"title":"Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease.","authors":"Stefana Enachi, Maxime Schleef, Chahr-Eddine Hadjseyd, Simon Leboube, Charles Fauvel, Lucie Daniel, Antoine Jobbe-Duval, Laurent Sebbag, Sandrine Lemoine, Nathan Mewton","doi":"10.1007/s11897-023-00594-1","DOIUrl":"https://doi.org/10.1007/s11897-023-00594-1","url":null,"abstract":"Purpose of review: Chronic kidney disease (CKD) is highly prevalent in patients with heart failure and reduced ejection fraction (HFrEF), representing a major factor of adverse outcomes. In clinical practice, it is one of the main reasons for not initiating, not titrating, and even withdrawing efficient heart failure drug therapies in patients.Recent findings: Despite limited data, studies show that HFrEF therapies maintain their benefits on cardiovascular outcomes in patients with CKD. Most HF drugs cause acute renal haemodynamic changes, but with stabilisation or even improvement after the acute phase, thus with no long-term worsening of the renal function. In this expert opinion-based paper, we challenge the pathophysiology misunderstandings that impede HF disease-modifying therapy implementation in this setting and propose a strategy for HF drug titration in patients with moderate, severe, and end-stage chronic kidney disease.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 2","pages":"101-112"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9780265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure and Multimorbidity in Asia. 亚洲的心力衰竭和多病。

Current Heart Failure Reports Pub Date : 2023-02-01 DOI: 10.1007/s11897-023-00585-2

Nathalie Ang, Chanchal Chandramouli, Kelvin Yiu, Claire Lawson, Jasper Tromp

{"title":"Heart Failure and Multimorbidity in Asia.","authors":"Nathalie Ang, Chanchal Chandramouli, Kelvin Yiu, Claire Lawson, Jasper Tromp","doi":"10.1007/s11897-023-00585-2","DOIUrl":"https://doi.org/10.1007/s11897-023-00585-2","url":null,"abstract":"Purpose of the review: Multimorbidity, the presence of two or more comorbidities, is common in patients with heart failure (HF) and worsens clinical outcomes. In Asia, multimorbidity has become the norm rather than the exception. Therefore, we evaluated the burden and unique patterns of comorbidities in Asian patients with HF.Recent findings: Asian patients with HF are almost a decade younger than Western Europe and North American patients. However, over two in three patients have multimorbidity. Comorbidities usually cluster due to the close and complex links between chronic medical conditions. Elucidating these links may guide public health policies to address risk factors. In Asia, barriers in treating comorbidities at the patient, healthcare system and national level hamper preventative efforts. Asian patients with HF are younger yet have a higher burden of comorbidities than Western patients. A better understanding of the unique co-occurrence of medical conditions in Asia can improve the prevention and treatment of HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 1","pages":"24-32"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9477685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

What Is the Clinical Utility of Cardiac Troponins in Heart Failure? Are They Modifiable Beyond Their Prognostic Value? 心脏肌钙蛋白在心力衰竭中的临床作用是什么？它们是否可以超越其预测价值进行修改？

Current Heart Failure Reports Pub Date : 2023-02-01 Epub Date: 2023-01-31 DOI: 10.1007/s11897-023-00588-z

David Agdashian, Lori B Daniels

引用次数: 1

Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure. 抗癌放射治疗的心脏毒性:对心力衰竭的关注。

Current Heart Failure Reports Pub Date : 2023-02-01 DOI: 10.1007/s11897-023-00587-0

Alex Ritter, Cooper Quartermaine, Jovan Pierre-Charles, Suryakumar Balasubramanian, Pejman Raeisi-Giglou, Daniel Addison, Eric Miller

{"title":"Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure.","authors":"Alex Ritter, Cooper Quartermaine, Jovan Pierre-Charles, Suryakumar Balasubramanian, Pejman Raeisi-Giglou, Daniel Addison, Eric Miller","doi":"10.1007/s11897-023-00587-0","DOIUrl":"https://doi.org/10.1007/s11897-023-00587-0","url":null,"abstract":"Purpose of review: As the percentage of patients achieving long-term survival following treatment of their cancer grows, it is increasingly important to understand the long-term toxicities of cancer-directed treatment. In this review, we highlight the recent findings regarding radiation-induced cardiotoxicity across multiple disease sites, with a particular focus on heart failure.Recent findings: Despite its relative lack of study historically, radiation-induced heart failure has now recently been implicated in several studies of breast cancer, lung cancer, esophageal cancer, and lymphoma as a non-trivial potential consequence of thoracic radiotherapy. Data regarding specific cardiac dosimetric endpoints relevant to cardiotoxicity continue to accumulate. Radiation-induced heart failure is a rare but significant toxicity of thoracic radiotherapy, that is likely underreported. Important areas for future focus include understanding the interplay between thoracic radiotherapy and concurrent cardiotoxic systemic therapy as well as development of potential mitigation strategies and novel therapeutics.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 1","pages":"44-55"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9636193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies. 动脉高血压和高血压介导的器官损伤在抗癌治疗的心脏毒性中的作用。

Current Heart Failure Reports Pub Date : 2023-02-01 DOI: 10.1007/s11897-023-00590-5

Giacomo Tini, Giuliano Tocci, Allegra Battistoni, Matteo Sarocchi, Camilla Pietrantoni, Domitilla Russo, Beatrice Musumeci, Carmine Savoia, Massimo Volpe, Paolo Spallarossa

{"title":"Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.","authors":"Giacomo Tini, Giuliano Tocci, Allegra Battistoni, Matteo Sarocchi, Camilla Pietrantoni, Domitilla Russo, Beatrice Musumeci, Carmine Savoia, Massimo Volpe, Paolo Spallarossa","doi":"10.1007/s11897-023-00590-5","DOIUrl":"https://doi.org/10.1007/s11897-023-00590-5","url":null,"abstract":"Purpose of the review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.Recent findings: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 1","pages":"56-62"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9472243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence? 心脏植入式电子设备的远程监测:证据是什么?

Current Heart Failure Reports Pub Date : 2023-02-01 DOI: 10.1007/s11897-023-00586-1

Adrian Reinhardt, Rodolfo Ventura

{"title":"Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence?","authors":"Adrian Reinhardt, Rodolfo Ventura","doi":"10.1007/s11897-023-00586-1","DOIUrl":"https://doi.org/10.1007/s11897-023-00586-1","url":null,"abstract":"Purpose of review: This review offers an overview of the evidence in diagnostic and therapeutic applications of remote monitoring implantable devices.Recent findings: Remote monitoring of cardiac implantable devices has become more and more popular in recent years as healthcare is moving towards a more patient centralized system. For heart failure patients with an ICD or pacemaker, there is controversial evidence regarding improvements in the clinical outcome, e.g., reduction of hospitalization rates or overall mortality. New developments as hemodynamic remote monitoring via measurement of the pulmonary artery pressure are promising technical achievements showing encouraging results. In cardiac remote monitoring of syncope and arrhythmias, implantable loop recorder plays an important role in diagnostic algorithms. Although there is controversial evidence according to remote monitoring of implantable devices, its use is rapidly expanding, giving healthcare providers the opportunity to react promptly to worsening of their patients. Adequate evaluation of the data created by remote monitoring systems remains an unsolved challenge of contemporary healthcare services.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 1","pages":"12-23"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9842752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Involvement in Mitochondrial Disorders. 线粒体疾病与心脏的关系。

Current Heart Failure Reports Pub Date : 2023-02-01 DOI: 10.1007/s11897-023-00592-3

Tudor-Alexandru Popoiu, Jan Dudek, Christoph Maack, Edoardo Bertero

引用次数: 2